Next Generation HCV Therapy Presented at the International Liver Congress™ 2017 by Texas Liver Institute’s Dr. Fred Poordad | Company Newsroom of Texas Liver Institute

Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies San Antonio, Texas, April 27, 2017 (Newswire.com) – Dr. Fred Poordad, internationally recognized for his research in the field of liver diseases, presented a retreatment study of patients who have failed...

Read More

MAGELLAN-I: Novel regimen yields strong results in experienced patients with RAVs

BARCELONA —  Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a pangenotypic NS5A inhibitor, produced sustained virologic response rates around 90% in a cohort of treatment-experienced patients, including those with resistance-associated variants, according to findings presented at the International Liver Congress. Fred Poordad, MD, of The...

Read More